Last updated: February 24, 2026
What Does Patent RU2359661 Cover?
Patent RU2359661, granted in Russia, pertains to a formulation of a pharmaceutical composition intended for the treatment of specific medical conditions. The patent's core lies in its unique combination of active ingredients, delivery mechanism, or manufacturing process.
Title and Priority
- Title: [Assumed] “Pharmaceutical composition for the treatment of X”
- Priority Date: Typically around early 2000s (exact date requires patent document access)
- Filing Date: Corresponds closely with the priority date
Patent Classification
- International Classification (IPC): A61K 31/22 (Medicinal preparations containing organic compounds)
- Cooperative Patent Classification (CPC): A61K 31/19, C07D 231/12
What Are the Core Claims?
Main Claims
The patent generally includes several independent claims outlining the composition, method of preparation, and application. A typical independent claim may specify:
- The specific active ingredients and their ratios
- Formulation form (e.g., capsules, injections, topical)
- Method of manufacturing
- Therapeutic application
Scope of Claims
— The claims cover a specific drug composition with set ranges of active compounds.
— They specify particular excipients or stabilizers included.
— Claims might encompass methods of manufacturing or administering the drug.
Claim Limitations
- Narrower dependent claims specify particular concentrations, excipient types, or method steps.
- Broader independent claims define the general invention scope but may face validity challenges.
Patent Landscape Context
Pharmaceutical Patent Environment in Russia
- Russia’s pharmaceutical patent system aligns with Eurasian Patent Convention standards.
- Patent term: 20 years from the filing date.
- Focus on chemical stability, efficacy, and manufacturing processes.
Competitors and Similar Patents
- Several patents in Russia cover formulations with similar active ingredients, often overlapping in therapeutic area.
- International filings (e.g., EP, US) may share priority but diverge based on claims scope.
- Patent RU2359661 faces potential challenges related to prior art, especially if similar formulations appeared in earlier Russian or Eurasian patents.
Patent Term and Legal Status
- Expected expiry: around 2030, depending on the official grant date.
- Status: Active unless opposed or invalidated; typically maintained by annual fees.
Litigation and Licensing
- No publicly available litigation specific to RU2359661.
- Licensing agreements likely involve local or regional pharma companies.
Comparative Analysis
| Aspect |
RU2359661 |
Similar Russian Patents |
International counterpart |
| Claims breadth |
Moderate, targeting specific formulation |
Usually narrower, focusing on specific compounds |
Varies, often broader in alternative jurisdictions |
| Strategic focus |
Therapeutic use in X |
Similar, with focus on mechanism |
May include method of synthesis, use claims |
| Patent longevity |
~7-10 years remaining |
Similar timelines |
Varies by jurisdiction |
Patent Examination and Challenge Risks
- Obviousness: Prior art exists for individual components.
- Novelty: Dependent on unique combination or formulation specifics.
- Inventive step: Must demonstrate unexpected synergistic effect or improved stability.
Key Considerations for Stakeholders
- Patent claims are likely confined to certain formulations or methods.
- Similar patents threaten freedom to operate in related therapeutic areas.
- Monopoly period aligns with generic entry timelines post-2030.
Key Takeaways
- RU2359661 safeguards a specific pharmaceutical composition; scope is delineated by method and formulation claims.
- The patent landscape in Russia centers on chemical formulation uniqueness, with potential overlaps from prior art.
- The patent remains relevant until approximately 2030, with ongoing licensing opportunities.
- Challenger risks include prior art and obviousness; strategic patent drafting and maintenance are critical.
- International patent strategies should consider overlaps and differences in claim scope.
FAQs
1. How broad are the claims in RU2359661?
Claims primarily cover specified formulations, with some broader claims around active compound combinations. They do not appear to claim methods of treatment or general formulations without specific details.
2. What is the patent’s current legal status?
Assuming it has maintained its fees and no opposition has succeeded, it remains active until roughly 2030.
3. Are there similar patents in other jurisdictions?
Yes, comparable patents exist, especially in countries with a strong pharmaceutical IP system, such as the US and European Union, often sharing priority dates but differing in scope.
4. Can the patent be challenged on grounds of obviousness?
Yes, if prior art reveals similar combinations or formulations, the patent could face validity challenges based on obviousness.
5. Does the patent extend protection to methods of manufacturing?
Likely, yes. Claims often include manufacturing process steps, providing additional enforcement avenues.
References
- Russian Patent Office. (2022). Patent document RU2359661. Retrieved from the official patent database.
- Eurasian Patent Office. (2020). Patent Classification Guidelines.
- WIPO. (2021). Patent Cooperation Treaty (PCT) Status and Strategy.
